Dermatitis News and Research

Latest Dermatitis News and Research

PhotoMedex to host free seminar to fight against psoriasis with XTRAC Excimer Lasers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

16 Nov 2009

Occupational contact dermatitis and asthma are most common work-related health issues, says new research

Occupational contact dermatitis and asthma are two of the most common work-related health issues facing workers worldwide, according to experts presenting the latest research at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

11 Nov 2009

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan(®) Photodynamic Therapy (PDT) may reduce the rate of recurrence of squamous cell carcinomas (SCCs) in solid organ transplant recipients (SOTRs), a population with a high incidence of nonmelanoma skin cancer.

10 Nov 2009

Safeguard Scientifics reports financial results for the third quarter of 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that third quarter consolidated net loss from continuing operations attributable to Safeguard common shareholders was $11.6 million, or $0.57 per share, compared with a net loss of $4.1 million, or $0.20 per share, in the same period of 2008.

4 Nov 2009

HER2-positive breast cancer patients can be treated with Trastuzumab and adjuvant radiation therapy

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)--typically used in combination with chemotherapy.

4 Nov 2009

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Raycop, the first handheld anti-bacterial vacuum cleaning system and part of the Earlex® brands, offers a proven way to fight the H1N1 virus in the home with its UVC technology. The vac's effects against the virus have been independently tested by a leading international laboratory in August.

3 Nov 2009

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

TomoTherapy Incorporated announced today that several clinical presentations at the American Society for Radiation Oncology's 51st ASTRO Annual Meeting -- November 1-5, 2009 in Chicago -- will showcase the use of the TomoTherapy® radiation therapy platform as a vital component in the combined modality approach to treating cancer.

30 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

PhotoMedex, Inc. a leading provider of advanced dermatology, clinical skincare and medical laser products, is hosting a free seminar in Indianapolis, IN on November 17, 2009.

28 Oct 2009

Toxic chemicals in face paints can cause skin sensitization and contact dermatitis

Ghosts and goblins aren't the only spooky things lurking around this Halloween. A new report by the Campaign for Safe Cosmetics reveals that popular children's face paints contain lead, a potent neurotoxin, as well as nickel, cobalt and chromium, which can cause lifelong skin sensitization and contact dermatitis.

28 Oct 2009

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the “Company”), a medical device company focused on infectious disease and dermatology, today provided an update to a previously announced exclusive cooperative research and development (the "Agreement”) with MAST BioSurgery Inc. (“MAST”) for the development of one or more new surgical products incorporating Ceragenix’s CeraShield™ antimicrobial technology.

26 Oct 2009

PhotoMedex announces the closure of private placement, raises $2.7 million

PhotoMedex, Inc. today announced that it has closed a private placement of approximately 4.17 million shares of its common stock at a price of $0.65 per share. Gross proceeds from the private placement are approximately $2.7 million. The purchasers were accredited investors, some of which were institutions.

24 Oct 2009

BioWa, NKT Therapeutics sign licensing agreement

BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

21 Oct 2009

BioTech Medics' SHBAN Hand Sanitizer Solution kills H1N1 Influenza A virus

BioTech Medics, Inc. announces that it has received independent clinical testing results of its SHBAN™ Hand Sanitizer Solution to prove SHBAN™ kills the H1N1 (Swine) Influenza A virus.

15 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

First prescription foam formulation of benzoyl peroxide available

Onset Therapeutics, a specialty pharmaceutical company focused on dermatology, announced today the commercial availability of BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Welichem announces filing of clinical trial application with Health Canada

Welichem Biotech Inc. (the "Company") announces the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded clinical trial in patients with chronic atopic dermatitis at three trial centres.

1 Oct 2009

Dermatitis News and Research

Latest Dermatitis News and Research

PhotoMedex to host free seminar to fight against psoriasis with XTRAC Excimer Lasers

Occupational contact dermatitis and asthma are most common work-related health issues, says new research

Levulan PDT may reduce the rate of recurrence of SCCs in solid organ transplant recipients: Study

Safeguard Scientifics reports financial results for the third quarter of 2009

HER2-positive breast cancer patients can be treated with Trastuzumab and adjuvant radiation therapy

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

TomoTherapy radiation therapy platform to be presented at the ASTRO Annual Meeting

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Seminar on XTRAC Velocity Laser treatments for psoriasis sufferers

Toxic chemicals in face paints can cause skin sensitization and contact dermatitis

Ceragenix Pharmaceuticals updates its cooperative research and development with MAST BioSurgery

PhotoMedex announces the closure of private placement, raises $2.7 million

BioWa, NKT Therapeutics sign licensing agreement

BioTech Medics' SHBAN Hand Sanitizer Solution kills H1N1 Influenza A virus

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

YM BioSciences to acquire Cytopia

First prescription foam formulation of benzoyl peroxide available

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Welichem announces filing of clinical trial application with Health Canada

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Dermatitis News and Research

Latest Dermatitis News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in